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Abstract
Objective To investigate the effects on cardiovascular outcomes of drug
interventions that increase high density lipoprotein levels.
Design Meta-analysis.
Studies reviewed Therapeutic benefit of niacin, fibrates, and cholesteryl
ester transfer protein (CETP) inhibitors on cardiovascular events (all
cause mortality, coronary heart disease mortality, non-fatal myocardial
infarction, and stroke).
Results 117 411 patients were randomised in a total of 39 trials. All
interventions increased the levels of high density lipoprotein cholesterol.
No significant effect was seen on all cause mortality for niacin (odds
ratio 1.03, 95% confidence interval 0.92 to 1.15, P=0.59), fibrates (0.98,
0.89 to 1.08, P=0.66), or CETP inhibitors (1.16, 0.93 to 1.44, P=0.19);
on coronary heart diseasemortality for niacin (0.93, 0.76 to 1.12, P=0.44),
fibrates (0.92, 0.81 to 1.04, P=0.19), or CETP inhibitors (1.00, 0.80 to
1.24, P=0.99); or on stroke outcomes for niacin (0.96, 0.75 to 1.22,
P=0.72), fibrates (1.01, 0.90 to 1.13, P=0.84), or CETP inhibitors (1.14,
0.90 to 1.45, P=0.29). In studies with patients not receiving statins (before
the statin era), niacin was associated with a significant reduction in
non-fatal myocardial infarction (0.69, 0.56 to 0.85, P=0.0004). However,
in studies where statins were already being taken, niacin showed no
significant effect (0.96, 0.85 to 1.09, P=0.52). A significant difference
was seen between these subgroups (P=0.007). A similar trend relating
to non-fatal myocardial infarction was seen with fibrates: without statin
treatment (0.78, 0.71 to 0.86, P<0.001) and with all or some patients
taking statins (0.83, 0.69 to 1.01, P=0.07); P=0.58 for difference.
Conclusions Neither niacin, fibrates, nor CETP inhibitors, three highly
effective agents for increasing high density lipoprotein levels, reduced
all cause mortality, coronary heart disease mortality, myocardial
infarction, or stroke in patients treated with statins. Although observational
studies might suggest a simplistic hypothesis for high density lipoprotein
cholesterol, that increasing the levels pharmacologically would generally
reduce cardiovascular events, in the current era of widespread use of
statins in dyslipidaemia, substantial trials of these three agents do not
support this concept.
Introduction
The discovery that raised low density lipoprotein and low high
density lipoprotein levels are associated with an increased
cardiovascular mortality1 2 encouraged the development of
targeted drug treatments. The primary aim of these drugs was
to increase high density lipoprotein levels or lower low density
lipoprotein levels, to prevent an increase in cardiovascular
disease, the single greatest cause of death worldwide.3
Reduction in low density lipoprotein levels with statins has
repeatedly been found to reduce cardiac events and all cause
mortality in the setting of both secondary and primary
prevention.4 Statins are available generically at low cost.
Attention has now turned to targeting levels of high density
lipoprotein in the hope of similar large benefits.
The three main agents proposed to increase high density
lipoprotein levels to reduce cardiovascular morbidity and
mortality are niacin, fibrates, and the recently developed
cholesterylester transfer protein (CETP) inhibitors. We
conducted a meta-analysis of randomised controlled trials of
these three classes of agents to determine their effects on
mortality and cardiovascular events.
Methods
We included all published and unpublished randomised
controlled trials that compared niacin, fibrates, or CETP
inhibitors against a control with or without concurrent statin
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treatment. No language restrictions were applied. We searched
Medline (1966 to 5 May 2013), the Cochrane Central Register
of Randomised Controlled Trials (to 5May 2013), and theWHO
International Clinical Trials Registry Platform search portal (to
5 May 2013) using search terms that included randomised
controlled trial and drug family names (niacin, fibrates, and
CETP inhibitors), and drug names within each class.
Supplementary appendix 1 provides the full search terms. We
additionally hand searched previous meta-analyses and reviews
and included results presented at recent conferences before
formal publication.
Two authors (DK and CP) carried out the literature search. Three
authors (DK, CP,MJS-S) extracted data and assessed the quality
of the trials independently in triplicate using a standardised
approach. Disagreements were resolved through consensus with
the help of an additional author (DPF). To be eligible for
inclusion, the trials had to be completed randomised controlled
trials that assessed the effects of the intervention compared with
a control group and that reported one or more of our primary
or secondary outcomes. We used the Cochrane Collaboration’s
tool for assessing risk of bias for quality assessment.
The primary outcome was all cause mortality on an intention
to treat basis. This endpoint is highly relevant and has the least
risk of bias. Secondary outcomes were coronary heart disease
mortality, non-fatal myocardial infarction, stroke, and reported
important adverse events. Sincemost patients with abnormalities
in lipid levels are currently treated with statins we separated the
trials into those in which there was no statin treatment compared
with those in which some or all of the participants received
statin treatment.
Event rates were extracted from the studies. We used the I2
statistic to assess for heterogeneity. When no significant
heterogeneity was detected we performed a random effects
meta-analysis in RevMan (version 5.2) using the
Mantel-Haenszel odds ratio and risk difference for harm.
Results
The literature searches identified 387 publications of niacin,
749 of fibrates, and 263 of CETP inhibitors that potentially met
our criteria. Of these there were 11 eligible trials of niacin, 20
of fibrates, and eight of CETP inhibitors. Two trials were of
niacin and fibrate in combination compared with control (see
supplementary appendix 2).
In one trial9 niacin was part of combination treatment with
colestipol, with the control arm receiving neither. In two trials5 14
niacin and a fibrate were part of a combination treatment, with
the control arms receiving neither. We included these two trials
in both the niacin and fibrate analyses, and we performed a
sensitivity analysis with them excluded (see supplementary
appendix 5).
Niacin
Description of included studies
Eleven completed randomised controlled trials5-15 enrolling 35
301 patients, lasting between six and 60 months, reported the
effects of niacin on the included outcomes (table 1⇓). Of these,
30 310 patients6 7 11-13 were in trials with statin used by some or
all the patients, and 4991 patients were in trials with no statin
treatment.5 8-10 14 15 The most recent trial, HPS2-Thrive, has
announced its outcome data, which we have included in this
meta-analysis.
Assessment of quality
Concealing allocation with niacin is challenging because of the
high risk of flushing. In one attempt to ameliorate this
unavoidable unblinding, participants were given a small dose
of niacin in the placebo6 on the assumption that this would be
enough to cause flushing but not enough to prevent events.
Another approach has been to add agents to inhibit the flushing
effect, such as aspirin9 11 or laropiprant.12 Laropiprant is thought
to work by modifying prostaglandin pathways. It is possible,
however, that its effect could confound the effect of niacin. One
study did not make a special attempt to obscure this effect and
might therefore be argued to be unblinded.14 A higher cessation
of treatment was seen in the niacin compared with the placebo
group in most of the studies,6 8 10-12 14 predominantly as a result
of the unpleasant side effect of facial flushing.
The assessment of risk of bias can be found in supplementary
appendix 3a.
Efficacy on cardiovascular endpoints
Overall, niacin had no net effect on all cause mortality (odds
ratio 1.03, 95% confidence interval 0.92 to 1.15, P=0.59). No
statistically significant difference (P=0.10) was seen in studies
conducted with statin treatment (1.10, 1.00 to 1.21, P=0.06) or
without (0.86, 0.65 to 1.14, P=0.29, fig 1⇓).
Neither was there any significant effect across all trials on the
secondary outcomes of coronary heart disease mortality (0.93,
0.76 to 1.12, P=0.44), non-fatal myocardial infarction (0.85,
0.72 to 1.01, P=0.07), or stroke (0.96, 0.75 to 1.22, P=0.72, see
table 4).
In studies conducted without statin treatment a significant benefit
was seen for the outcomes of non-fatal myocardial infarction
(0.69, 0.56 to 0.85, P=0.0004) and stroke (0.78, 0.61 to 1.00,
P=0.05). This effect was not, however, seen in studies conducted
with statin treatment (0.96, 0.85 to 1.09, P=0.52 and 1.10, 0.70
to 1.74, P=0.68, respectively). The difference between these
subgroups was statistically significant for non-fatal myocardial
infarction (P=0.007) but not for stroke (P=0.19).
Reported adverse events
Niacin is known to cause flushing. This was clearly reported
on in four trials.6 11-13 Of these trials, one gave a small dose of
niacin to the placebo group,6 one recommended that participants
took aspirin,11 one gave laropiprant,12 and one was unblinded.13
Across these trials, the risk difference in the development of an
adverse skin effect was 0.05 (95% confidence interval 0.03 to
0.07, P<0.001), and heterogeneity between trials was significant
(I2=86%).
The HPS2-Thrive study reported multiple new signals for
possible harm, including infection, gastrointestinal
complications, bleeding, complications of diabetes, and
musculoskeletal side effects (see supplementary appendix 7).
Fibrates
Description of included studies
Twenty completed randomised controlled trials5 8 14 16-32 enrolling
46 099 patients, lasting between 12 and 85 months, reported
the effects of fibrates on the included outcomes (table 2⇓). One
study had to be excluded as it did not report extractable data on
our endpoints.19 In two of the studies26 28 some or all of the
patients were receiving statin treatment (100% and 26%,
respectively).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4379 doi: 10.1136/bmj.g4379 (Published 18 July 2014) Page 2 of 13
RESEARCH
Assessment of quality
Early trials14 20 22-24 presented limited data on the key aspects of
trial quality, such as randomisation andmaintenance of blinding.
More recent trials17 26-28 showed better evidence of good quality
design, with satisfactory central randomisation using block
design stratification with clear central event adjudication, and
methods in place to ensure maintenance of double blinding.
Dropout rates were high in several trials14 26 31 partly perhaps
because of publicity surrounding the publishedWHOClofibrate
study,25 which reported an increased mortality for patients
receiving fibrates.
The assessment of risk of bias can be found in supplementary
appendix 3b.
Effect on cardiovascular endpoints
All cause mortality was not found to be significantly affected
by fibrate treatment (odds ratio 0.98, 95% confidence interval
0.89 to 1.08, P=0.66). Heterogeneity across the 20 trials was
moderate (I2=33%). No statistically significant difference was
seen in all cause mortality in studies conducted with statin
treatment (1.01, 0.83 to 1.24, P=0.12)26 28 or without (0.96, 0.86
to 1.09, P=0.55)5 8 14 16-18 20-27; P=0.67 for difference between the
subgroups (fig 2⇓).
Neither coronary heart disease mortality (0.92, 0.81 to 1.04,
P=0.19) nor stroke (1.01, 0.90 to 1.13, P=0.84) were found to
be significantly affected by fibrates across all trials. Overall,
however, non-fatal myocardial infarction was found to be
reduced (0.80, 0.74 to 0.87, P<0.001) (see table 4). This effect
was statistically significant in the trials without statin treatment
(0.78, 0.71 to 0.86, P<0.001), but not in those with statin
treatment (0.83, 0.69 to 1.01, P=0.07). The difference between
these subgroups was not significant (P=0.58).
Reported adverse events
Across three trials, fibrates were associated with a small
statistical increase in pulmonary emboli (risk difference 0.01,
95% confidence interval 0.00 to 0.01, P=0.002). Other reported
adverse effects are included in supplementary appendix 7.
CETP inhibitors
Description of included studies
Eight completed randomised controlled trials33-40 enrolling 36
011 patients examined three agents in this class: anacetrapib,
dalcetrapib, and torcetrapib (table 3⇓). All randomisations were
between the addition of CETP inhibitor and placebo, with
virtually all patients receiving statin treatment. Duration of
follow-up ranged from eight months to 31 months. Two more
trials, ACCELERATE (NCT01687998) and HPS3/TIMI-55
(REVEAL, NCT01252953), are underway, and are expected to
finish in January 2016 and January 2017, respectively.
Assessment of quality
Most trials used electronic central random sequence
generation.33-35 40 In many33 34 36-38 there was an external
adjudication committee blinded to the endpoint. In all studies
both the patients and the assessors were blinded. In six studies
patients and staff were also blinded to follow-up cholesterol
levels.33-36 39 40 In one study37 the CETP inhibitor arm had a higher
dropout rate than the control arm, as well as a higher adverse
event rate, including more hypertension and diarrhoea. Two of
the studies involving torcetrapib 37 40were stopped early because
of adverse events in the treatment arms, and one involving
dalcetrapib33 due to futility.
The assessment of risk of bias can be found in supplementary
appendix 3c.
Effect on cardiovascular endpoints
Torcetrapib was found to significantly increase mortality (odds
ratio 1.53, 95% confidence interval 1.12 to 2.09, P=0.007). This
effect was not seen with anacetrapib (1.38, 0.55 to 3.45, P=0.49)
or with dalcetrapib (0.98, 0.81 to 1.18, P=0.82). The differences
between these subgroups was significant (I2=67.4%, P=0.05,
fig 3⇓). When considering only anacetrapib and dalcetrapib,
mortality was found not to be significantly affected (0.99, 0.83
to 1.19, P=0.93).
CETP inhibitors were found to have no significant effect on
coronary heart disease mortality (1.00, 0.80 to 1.24, P=0.31),
non-fatal myocardial infarction (1.05, 0.93 to 1.18, P=0.41), or
stroke (1.14, 0.90 to 1.45, P=0.29). Table 4⇓ summarises these
results.
Reported adverse events
As well as the increased risk of mortality associated with
torcetrapib, the rate of hypertension was found to be increased
(risk difference 0.10, 95% confidence interval 0.06 to 0.14).
This effect was not seen with the other CETP inhibitors.
Dalcetrapib was associated with a significant increase in
diarrhoea (0.02, 0.02 to 0.03, P<0.001). Supplementary appendix
7 shows the other reported side effects.
Forest plots for all endpoints are available in supplementary
appendix 4. A funnel plot for each agent for the endpoint of all
cause mortality is shown in supplementary appendix 6. The
funnel plots did not suggest publication bias.
Discussion
The three classes of agents studied in this meta-analysis (niacin,
fibrates, and cholesteryl ester transfer protein (CETP) inhibitors),
targeted at increasing high density lipoprotein levels, were not
associated with a significantly reduced risk of all cause mortality
and coronary heart disease mortality. This was the case in both
the pre-statin era and the present era of widespread use of statins
for cardiovascular event reduction. One agent for increasing
high density lipoprotein levels, torcetrapib, did significantly
change mortality, but this was an increase.
The statin era
Without background treatment with statins, fibrates were seen
to reduce non-fatal myocardial infarction, and niacin to reduce
both non-fatal myocardial infarction and stroke. However, in
the modern era when treatment with statins is standard, this
effect has not been apparent (fig 4⇓). Attempts at risk reduction
through these treatments to increase high density lipoprotein
levels on top of statin treatment have been unsuccessful so far.
Over-simplistic high density lipoprotein
hypothesis?
With the impending flooding of the marketplace with low cost
generic statins, it was rational for investment in preventive lipid
modifying treatment to be directed towards non-statin
interventions. The consistent finding in observational studies,41-44
that an increased high density lipoprotein cholesterol level is
associated with lower cardiovascular risk, made the increasing
of high density lipoprotein levels a logical aim in drug
development.
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However it seems that in the statin era these three agent classes
to increase high density lipoprotein levels have not been able
to prevent clinically important events. This is despite the
observational association that each 0.1 mmol/L higher high
density lipoprotein level is associated with a 50-80% reduction44
in coronary heart disease events.
For example, in the DEFINE study of anacetrapib,36 the effect
size on high density lipoprotein level was 1.4 mmol/L, which
would correspond to a 66% to 89% reduction in cardiovascular
events, quite apart from any event reduction through other
mechanisms (for example, low density lipoprotein was
approximately halved).
It could be argued that the studies so far have selected
inappropriate candidates to study. Individual doctors sometimes
feel confident that they can make better selections in daily
practice. It should be remembered, however, that the companies
planning substantial investment in trials took considerable care
to select appropriate cohorts. None of these selections delivered
net benefit on clinical endpoints in the statin era.
A strength of our analysis is that the mechanisms through which
these three classes of agents increase high density lipoprotein
levels are distinctly different, and have different pleiotropic
effects. It is possible that, in each of the three cases a different
off-target effect may have neutralised an underlying benefit of
the drug. However, an alternative and arguably simpler
interpretation might be that interventions targeted at raising
high density lipoprotein levels should not be assumed to be
beneficial.
It could also be argued that the CETP inhibitors show promise,
with long term outcome trials underway. However, unless they
find event rates reduced by 75% to 95%, which is what would
be expected if the therapeutic impact of the changes in high
density and low density lipoprotein levels matched the
observational relations, we will never knowwhether the benefits
are mediated through raising high density lipoprotein levels,
lowering low density lipoprotein levels, or neither.
High density lipoprotein has subtypes and the molecule can
vary in degree of function. This study cannot comment about
whether an intervention that rebalances the distribution between
subtypes, or alters their function, would reduce cardiovascular
events. Adequately powered specific trials for this are as yet
unavailable. A genome wide mendelian randomisation study45
has provided a mechanistic basis for the observations in this
meta-analysis by finding numerous genes that affect high density
lipoprotein cholesterol levels without affecting the incidence
of myocardial infarction. This has removed a major premise
supporting the strategic aim of using drugs to increase high
density lipoprotein levels.
Causation
Caution is needed before a conclusion can be made that the
statins reduce mortality and the agents targeted at high density
lipoprotein do not. The possibility cannot be excluded that high
density lipoprotein targeted agents have a beneficial mortality
effect but simultaneously abolish the statin benefit, leaving a
net neutral effect. Nevertheless, how such abolition might occur
is unknown.
Multiple convincing molecular mechanisms
High density lipoprotein has been reported to have a panoply
of favourable properties,46 47 including anti-inflammatory,
antioxidant, and antithrombotic, and facilitating cholesterol
transport out of lesions. Nevertheless, some of these agents have
been associated with worrying signals. In the trials of
torcetrapib,37 38 which increased mortality, blood pressure was
also noted to be increased and it was hoped that this might be
the cause of the adverse outcomes so that these events could be
reduced by using an alternative agent. Unfortunately, and as
pointed out by the authors themselves, the increased mortality
was in patients with lower, not higher, blood pressure.
Furthermore, no mortality benefit was seen with the other two
agents in the class, which did not share this blood pressure
raising tendency.
Surrogate endpoint trials
Alongside trials of dichotomous endpoints, other trials have
also measured quantitative markers such as atheroma burden
through carotid intima media thickness, brachial flowmediated
dilation, coronary atheroma quantification by intravascular
ultrasonography, calculated angiographic lesion dimensions,
and angiographic percentage stenosis. In the pre-statin era many
of these trials9 10 15 16 27 showed a significant beneficial effect on
these surrogate markers when high density lipoproteins were
increased by drug treatment compared with placebo. Despite
impressive reductions in plaque burden being shown by these
studies, the decrease has not translated into reduction of
cardiovascular events. This mismatch is unexplained.
More recently the effect of these high density lipoprotein
targeted treatments on lesion characteristics used rigorous
techniques conducted in the statin era with a confirmed
noticeable increase in high density lipoprotein showed no
significant benefit on plaque burden.19 35 38-40 48
Clinical implications
A simple hypothesis that any drug intervention that successfully
increases high density lipoprotein levels will give additional
protection against important clinical events seems to be
incorrect. Trials are underway with agents that simultaneously
raise high density lipoprotein and lower low density lipoprotein
levels.
For now, we suggest that clinicians quantifying high density
lipoprotein for risk stratification should resist assuming that
patients’ cardiovascular risk will be reduced by using the three
classes of agents assessed here to raise high density lipoprotein.
Implications for research
Equally an over-simplistic hypothesis for low density lipoprotein
could also be considered doubtful. Only one class of agents, the
statins, has a large effect on low density lipoprotein cholesterol
levels and provides a large reduction in events. With statin
treatment in place, no incremental manipulation of cholesterol,
low density lipoprotein, or high density lipoprotein levels with
a non-statin agent has been found to prevent events so far.
Higher strength statin regimens do reduce events further in
secondary prevention,49 but this is not proof that the
accompanying lower low density lipoprotein level is the
mechanism of benefit. The multiple effects of statins might be
correlated in intensity across drug and dose. If so, effects on
lipids and effects on cardiovascular events would be correlated,
without the lipid reduction being the cause for the event
reduction.
Notably, fine grained temporal analysis shows reduction in
events from use of statins long before the plausible time at which
lower lipid levels could mediate slower accumulation of
atheroma and thereby could have had an effect.50 Whether the
decrease in low density lipoprotein cholesterol level is the
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principal mechanism for the reduction of acute events by statins
is, therefore, unknown.
Limitations of this study
Events were not necessarily adjudicated in the same way across
all trials. They were, however, adjudicated consistently within
individual trials and it was only the odds ratios from the trials
that we combined, which should minimise the impact of
differences in definitions between trials.
In our meta-analysis we only considered randomised controlled
trials with available results. We cannot exclude the possibility
that there were trials showing positive results but that these were
not reported, although such a direction of publication bias is
unusual.
We did not include non-randomised or uncontrolled studies
because of the potential for confounding and bias that can be
much larger than generally expected.51
Some trials had only a small numbers of events. Some used
niacin and fibrate in combination: we considered these to be
members of both the niacin and the fibrate groups. Sensitivity
analyses (see supplementary appendix 5) showed that without
these trials of combination treatment the effects are still neutral.
Follow-up duration varied considerably across the trials; not all
published a clear time to event analysis that might have allowed
effects to be explored more fully.
Meta-analyses of such outcome data do not allow elucidation
of mechanisms. Heterogeneity is reported in the particle size,
charge, and composition of high density lipoprotein, and
therefore level alone may be deemed an inadequate marker for
functionality. However, despite this, the three drug agents
studied were each considered to have a favourable effect on the
high density lipoprotein profile, yet all failed to achieve a
reduction in events when statin treatment was already in place.
Conclusions
The simple hypothesis that any agent that raises high density
lipoprotein levels should decrease cardiovascular events may
not be correct. Trials are underway of agents that raise high
density lipoprotein levels while simultaneously reducing low
density lipoprotein levels.
For patients who are unable to take statins, fibrates have been
shown to reduce non-fatal myocardial infarction, and niacin has
been shown to reduce both stroke and non-fatal myocardial
infarction, despite neither reducing all cause mortality. These
effects were, however, not seen in the current era of statin
treatment.
Attempts to reduce cardiovascular events or mortality by raising
high density lipoprotein levels using three dissimilar classes of
agents has, when trialled in the statin era, so far been
unsuccessful.
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Tables
Table 1| Description of included studies of niacin
Increase
in HDL
White
ethnicity
(%)
Mean (SD) age
(years)
(intervention,
control)
Men (No
intervention,
No control)
Statin
use
(%)
No enrolled
(No
intervention,
No control)
Follow-up
(months)ControlTrial drugs and doseReference
from
baseline
in active
arm (%)
36NR63.3 (7.5), 63.1
(6.8)
64, 680143 (71, 72)30Placebo
(cholestyramine if LDL
high)
Niacin 240 mg to 3 g,
gemfibrozil 600 mg twice
daily (cholestyramine 2 g/d
titrated to 16 g once daily if
LDL increased)
AFREGS5 2005
259263.7 (8.8), 63.7
(8.7)
1465, 14451003414 (1718,
1696)
36Placebo (contained 50
mg of immediate
release niacin in each
tablet), simvastatin
40-80 mg with or
without ezetimibe as
required
Niacin 1500-2000 mg,
simvastatin 40-80 mg with or
without ezetimibe as required
AIM HIGH6
2011
21NR67 (10), 68 (10)78, 74100167 (87, 80)12Placebo and statinNiacin extended release 500
mg for 30 days then 1000mg
and statin
ARBITER 27
2004
NR93NR1119, 278903908 (1119,
2789)
60Lactose placebo 3.8 g
daily
Niacin 3 gCDP 5 YR8
1975
379453.9 (0.5), 54.5
(0.5)
94, 940188 (94, 94)24PlaceboNiacin 3-12 g and 30 g
colestipol
CLAS91987
43NR47 (NR), 47 (NR)36, 460100 (48, 52)30Placebo (with or
without colestipol if
LDL increased)
Niacin 1 g four times daily
and colestipol 10 g three
times daily
FATS10 1990
30.28756.9 (10.9), 57.5
(10.3)
324, 152100948 (676, 272)6Ezetimbibe 10 mg
once daily,
simvastatin 20mg one
daily
Niacin titrated to 2 g and
ezetimibe 10 mg and
simvastatin 20 mg
GUYTON112008
17NR64.9 (NR), 64.9
(NR)
10 656, 10
653
10025673 (12 838,
12 835)
48Placebo, simvastatin
40 mg with or without
ezetimibe 10 mg
Niacin extended release 2 g
and laropiprant 40 mg,
simvastatin 40 mg with or
without ezetimibe 10 mg
HPS 2
THRIVE122013
(unpublished)
29NR72.88 (6.88),
68.83 (10.01)
27, 39100108 (52, 56)12Atorvastatin 10 mgNiacin extended release 500
mg for 30 days then 1 g for
12 months and atorvastatin
10 mg
SANG132009
NRNR61.1 (NR), 60.7
(NR)
219, 2230555 (279, 276)60Conventional
treatment
Niacin up to 1 g three times
daily and clofibrate 1 g twice
daily
STOCKHOLM14
1988
28NR41.4 (12), 42.4
(13)
18, 13097 (48, 49)26Conventional
treatment with or
without colestipol
Niacin up to 7.5 g daily,
colestipol 30 g daily,
losuvastatin was offered
towards end of trial
UCSF-SCOR15
1990
HDL=high density lipoprotein; LDL=low density lipoprotein; NR=not reported.
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Table 2| Description of included studies of fibrates
Increase
in HDL
White
ethnicity
(%)
Mean (SD) age
(years)
(intervention,
control)
Men (No
intervention,
No control)
Statin
use
(%)
No enrolled (No
intervention, No
control)
Follow-up
(months)ControlTrial drugs and doseReference
from
baseline
in active
arm (%)
9NR41 (NR), 41 (NR)47, 45092 (47, 45)60PlaceboBezafibrate 200 mg three
times daily
Becait161998
65650.8 (8.0), 50.9
(8.1)
61, 560164 (81, 83)36PlaceboBezafibrate 400 mg dailySENDCAP19
1998
8NR68.4 (8.9), 68.0
(8.8)
783, 78501568 (783, 785)74PlaceboBezafibrate 400 mg dailyLEADER182002
18NR60.1 (6.8), 60.1
(6.7)
1412, 141303090 (1548, 1542)74Placebo
(colestipol added
if LDL >180 from
1994)
Bezafibrate retard 400 mg
(colestipol added if LDL
>180 from 1994)
BIP172000
NRNR52 (NR), 54 (NR)192, 2080497 (244, 253)60PlaceboClofibrate 1.5-2 gNewcastle221971
NRNRNR288, 3050717 (350, 367)72PlaceboClofibrate 1.6-2 gScottish231971
NRNR45.9 (0.1), 45.8
(0.1)
5331, 5296010 627 (5331,
5296)
63PlaceboClofibrate 1.6 gWHOClofibrate25
1978
NRNR45.8 (8.8), 46.2
(7.0)
198, 2310662 (334, 328)60PlaceboClofibrate 1.6 gHanefeld
(Diabetes
Intervention
Study)211991
NR93NR1103, 278903892 (1103, 2789)60 month
data
reported
PlaceboClofibrate 1.8 gCDP fibrate 5yr8
1975
NRNR61.1 (NR), 60.7
(NR)
219, 2230555 (279, 276)60Conventional
treatment
Clofibrate 1 g twice daily
and niacin up to 1 g three
times daily
Stockholm141988
NRNRNR*68% overall095 (47, 48)85Matching corn oil
tablets for first 20
months. Then
swapped to
placebo tablets
Clofibrate 25 0mg (4 to 8×
daily dependent on body
weight)
Acheson201972
NR75.5NR268, 2640532 (268, 264)54PlaceboClofibrate 500 mg four
times daily
VA Neuro241973
86862.2 (6.7), 62.3
(6.9)
1914, 19101005518 (2765, 2753)56Placebo and
open label
simvastatin
Fenofibrate 160 mg once
daily and open label
simvastatin
Accord262010
59362.2 (6.8), 62.2
(2.9)
3071, 3067269795 (4895, 4900)60PlaceboFenofibrate 200 mg once
daily
Field282005
99657.4 (5.7), 56.3
(6.2)
149, 1560418 (207, 211)36PlaceboFenofibrate 200 mg once
daily
Dais272001
689.564 (7), 64 (7)1264, 126702531 (1264, 1267)61PlaceboGemfibrozil 1200 mg once
daily
VA-HIT321999
21NR58.8 (7.3), 59.5
(6.2)
197, 1980395 (197, 198)32PlaceboGemfibrozil 1200 mg once
daily
LOCAT311997
10NR47.2 (4.6), 47.4
(4.6)
2051, 203004081 (2051, 2030)60PlaceboGemfibrozil 600 mg twice
daily
HHS291987
8.6NR48.7 (NR), 48.6
(NR)
311, 3170628 (311, 317)60PlaceboGemfibrozil 600 mg twice
daily
HHSExclusions30
1993
36NR63.3 (7.5), 63.1
(6.8)
64, 680143 (71, 72)30Placebo
(cholestyramine if
LDL increased)
Gemfibrozil 600 mg twice
daily, niacin 240 mg to 3 g
once daily (cholestyramine
2 g/d titrated to 16 g once
daily if LDL increased)
AFREGS52005
HDL=high density lipoprotein; LDL=low density lipoprotein; NR=not reported.
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Table 3| Description of included studies of cholesteryl ester transfer protein (CETP) inhibitors
Increase in
HDL from
White
ethnicity
(%)
Mean (SD) age
(years) (intervention,
control)
Men (No
intervention,
No control)
Statin
use (%)
No enrolled (No
intervention, No
control)
Follow-up
(months)Control
Trial drugs and
doseReference
baseline in
active arm
(%)
408860.3 (9.1), 60.1 (9.1)6365, 64369715 871 (7938, 7933)31PlaceboDalcetrapib 600 mg
daily
Dal-
OUTCOMES33
2012
319262.6 (8.2), 64.6 (7.8)51, 5587130 (64, 66)24PlaceboDalcetrapib 600 mg
daily
Dal-PLAQUE34
2011
31NR62.3 (7.05), 61.9
(7.92)
211, 21195476 (239, 237)8PlaceboDalcetrapib 600 mg
daily
Dal-VESSEL35
2012
1388362.5 (8.7), 62.9 (9.0)629, 618991623 (811, 812)18PlaceboAnacetrapib 100 mg
daily
Define362010
729361.3 (7.6), 61.3 (7.6)5854, 586110015 054 (7528, 7526)18PlaceboTorcetrapib 60 mg
daily
Illuminate37 2007
61NR56.9 (9.1), 57 (9.2)416, 4211001188 (591, 597)24PlaceboTorcetrapib 60 mg
daily
Illustrate382007
52NR46.8 (12.0), 45.2
(12.9)
214, 232100850 (423, 427)24PlaceboTorcetrapib 60 mg
daily
Radiance 139
2007
63NR57.9 (8.1), 56.5 (8.2)237, 245100752 (377, 375)20PlaceboTorcetrapib 60 mg
daily
Radiance 240
2007
HDL=high density lipoprotein; NR=not reported.
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Table 4| Combined results of meta-analysis showing effect of niacin, fibrate, and cholesteryl ester transfer protein (CETP) inhibitors on
risk of all cause mortality, coronary heart disease mortality, non-fatal myocardial infarction, and stroke
P valueOdds ratio (Mantel-Haenszel random (95% CI)
No of events/Total
Events by drug class PlaceboIntervention
Niacin
All cause mortality:
0.591.03 (0.92 to 1.15)1486/18 2711194/17 030All trials
0.290.86 (0.65 to 1.1.4)669/3332299/1659Non-statin trials
0.061.10 (1.00 to 1.21)817/14 939895/15 371Statin trials
Coronary heart disease mortality:
0.440.93 (0.76 to 1.12)852/18 034565/16 795All trials
0.210.75 (0.48 to 1.18)527/32312225/1563Non-statin trials
0.571.05 (0.90 to 1.22)325/14 803340/15 232Statin trials
Non-fatal myocardial infarction:
0.070.85 (0.72 to 1.01)921/18271645/17030All trials
0.00040.69 (0.56 to 0.85)399/3332136/1659Non-statin trials
0.520.96 (0.85 to 1.09)527/14939509/15371Statin trials
Stroke:
0.720.96 (0.75 to 1.22)797/18 020620/16 788All trials
0.050.78 (0.61 to 1.00)278/318992/1517Non-statin trials
0.681.10 (0.70 to 1.74)519/14 883528/15 319Statin trials
Fibrates
All cause mortality:
0.660.98 (0.89 to 1.08)2123/23 7951763/22 140All trials
0.550.96 (0.86 to 1.09)1579/16 1421204/14 480Non-statin trials
0.891.01 (0.83 to 1.24)544/7653559/7660Statin trials
Coronary heart disease mortality:
0.190.92 (0.81 to 1.04)1032/23 536704/21 886All trials
0.050.88 (0.78 to 1.00)925/15 883582/14 226Non-statin trials
0.321.14 (0.88 to 1.49)107/7653122/7660Statin trials
Non-fatal myocardial infarction:
<0.0010.80 (0.74 to 0.87)1574/23 5491104/21 896All trials
<0.0010.78 (0.71 to 0.86)1181/15 896773/14 236Non-statin trials
0.070.83 (0.69 to 1.01)393/7653331/7660Statin trials
Stroke:
0.841.01 (0.90 to 1.13)772/22 404610/20 784All trials
0.481.06 (0.91 to 1.23)549/14 751401/13 124Non-statin trials
0.490.94 (0.77 to 1.13)223/7653209/7660Statin trials
CETP inhibitors
All trials:
0.191.16 (0.93 to 1.44)307/18 008340/18 003All cause mortality
0.991.00 (0.80 to 1.24)163/18 008163/18 003Coronary heart disease mortality
0.411.05 (0.93 to 1.18)553/18 008582/18 003Non-fatal myocardial infarction
0.291.14 (0.90 to 1.45)127/18 008143/18 003Stroke
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Figures
Fig 1 Forest plot showing effect of niacin on risk of all cause mortality, stratified by use of statin in trial
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Fig 2 Forest plot showing effect of fibrates on risk of all cause mortality stratified by different fibrate agents
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Fig 3 Forest plot showing effect of cholesteryl ester transfer protein (CETP) inhibitors on risk of all cause mortality stratified
by CETP inhibitors
Fig 4 The statin revolution: without background statin treatment, fibrates and niacin were found to reduce non-fatal myocardial
infarction. In the modern era, however, when background treatment of patients with dyslipidaemia typically includes statins,
this effect was not apparent
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